Janux Therapeutics Inc (JANX) AI Stock Analysis

714 Followers

Janux Therapeutics Inc

(NASDAQ:JANX)

Select Model

Rating:56Neutral

Price Target:$18.50▲(1.76% Upside)

Action:reiterated

Date:08/07/26

JANX scores mid-range primarily due to a strong balance sheet (very low leverage) and improving revenue momentum, offset by substantial ongoing losses and continued negative free cash flow. Technicals are modestly supportive, while valuation metrics are constrained by negative earnings and lack of dividend data.

Positive Factors

Low Financial LeverageMinimal leverage gives JANX meaningful financial flexibility while it funds research and development. Limited borrowing reduces near-term balance-sheet pressure and leaves greater capacity to absorb setbacks, support operations, or pursue development priorities without relying heavily on debt.

Negative Factors

Deeply Negative ProfitabilityJANX remains far from breakeven, with substantial operating costs associated with its research-heavy model. Deep losses reduce internal funding capacity and mean future financial progress depends on meaningful program advancement, revenue expansion, or continued access to external capital.

Janux Therapeutics Inc (JANX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.09B
Dividend Yield: ―
Average Volume (3M): 827.95K
Price to Earnings (P/E): -10.8
Beta (1Y): 1.19
Revenue Growth: 5366.97%
EPS Growth: 8.50%
Country: US
Employees: 113
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Janux Therapeutics Inc Business Overview & Revenue Model

Company Description

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the...

Janux Therapeutics Inc Financial Statement Overview

Summary

Mixed fundamentals: strong TTM revenue growth (~47.5%) and healthy gross margin (~68.9%) are positives, and the balance sheet is a major strength with very low leverage (debt-to-equity ~0.02). However, profitability remains deeply negative (TTM net margin ~-322%) and cash burn continues (TTM operating cash flow ~-$53.6M; free cash flow ~-$54.5M), keeping overall financial performance in the mid-range.

Income Statement

34Negative

Balance Sheet

78Positive

Cash Flow

40Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	24.00M	10.00M	10.59M	8.08M	8.61M	3.64M
Gross Profit	24.00M	7.97M	8.53M	6.13M	7.77M	-22.60M
EBITDA	-100.69M	-111.60M	-66.93M	-56.34M	-62.22M	-32.56M
Net Income	-102.59M	-113.63M	-68.99M	-58.29M	-63.06M	-32.67M
Balance Sheet
Total Assets	1.01B	1.01B	1.06B	380.41M	364.01M	379.82M
Cash, Cash Equivalents and Short-Term Investments	970.91M	966.57M	1.03B	344.03M	327.02M	374.96M
Total Debt	20.99M	22.14M	23.02M	24.54M	25.30M	194.00K
Total Liabilities	79.67M	50.70M	38.73M	36.06M	43.27M	13.50M
Stockholders Equity	927.98M	956.82M	1.02B	344.35M	320.74M	366.33M
Cash Flow
Free Cash Flow	-41.92M	-83.28M	-44.17M	-52.42M	-49.37M	-18.46M
Operating Cash Flow	-41.25M	-82.23M	-43.81M	-50.58M	-42.92M	-16.98M
Investing Cash Flow	7.35M	-300.98M	-258.02M	-41.19M	58.27M	-340.96M
Financing Cash Flow	9.22M	4.95M	713.24M	59.55M	500.00K	386.52M

Janux Therapeutics Inc Technical Analysis

Technical Analysis SentimentPositive

Last Price18.18

Price Trends

50DMA17.58Positive

100DMA16.64Positive

200DMA15.37Positive

Market Momentum

MACD0.09Negative

RSI55.14Neutral

STOCH55.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Positive. The current price of 18.18 is above the 20-day moving average (MA) of 17.41, above the 50-day MA of 17.58, and above the 200-day MA of 15.37, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 55.14 is Neutral, neither overbought nor oversold. The STOCH value of 55.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JANX.

Janux Therapeutics Inc Risk Analysis

Janux Therapeutics Inc disclosed 79 risk factors in its most recent earnings report. Janux Therapeutics Inc reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Janux Therapeutics Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JANX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JANX	56Neutral	$1.07B	-10.80	-10.79%	―	5366.97%	8.50%
IMCR	54Neutral	$1.53B	-166.56	-2.35%	―	20.19%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AGEN	50Neutral	$294.91M	2.46	-38.12%	―	30.47%	―
STTK	45Neutral	$533.93M	-10.72	-43.57%	―	-66.63%	57.89%
IMTX	42Neutral	$1.06B	-3.96	-47.04%	―	-65.40%	-164.71%
CTMX	34Underperform	$485.92M	-4.84	-38.46%	―	-87.03%	-179.91%

* Healthcare Sector Average

Performance Comparison

JANX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JANX	Janux Therapeutics, Inc.	18.18	-10.48	-36.57%
AGEN	Agenus Inc.	6.97	3.13	81.51%
CTMX	CytomX Therapeutics Inc.	2.35	-1.84	-43.91%
IMTX	Immatics N.V.	6.91	-2.32	-25.14%
STTK	Shattuck Labs, Inc.	5.15	3.19	162.76%
IMCR	Immunocore Holdings Plc	29.23	-2.36	-7.49%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 07, 2026

Janux Therapeutics Inc AI Stock Analysis